Damato, B.; Eleuteri, A.; Coupland, S.E.; Kalirai, H.; Heimann, H.
How Many Patients with Choroidal Melanoma Would Be Eligible for Neoadjuvant Systemic Therapy to Enable Ruthenium-106 Brachytherapy? Cancers 2025, 17, 3022.
https://doi.org/10.3390/cancers17183022
AMA Style
Damato B, Eleuteri A, Coupland SE, Kalirai H, Heimann H.
How Many Patients with Choroidal Melanoma Would Be Eligible for Neoadjuvant Systemic Therapy to Enable Ruthenium-106 Brachytherapy? Cancers. 2025; 17(18):3022.
https://doi.org/10.3390/cancers17183022
Chicago/Turabian Style
Damato, Bertil, Antonio Eleuteri, Sarah E. Coupland, Helen Kalirai, and Heinrich Heimann.
2025. "How Many Patients with Choroidal Melanoma Would Be Eligible for Neoadjuvant Systemic Therapy to Enable Ruthenium-106 Brachytherapy?" Cancers 17, no. 18: 3022.
https://doi.org/10.3390/cancers17183022
APA Style
Damato, B., Eleuteri, A., Coupland, S. E., Kalirai, H., & Heimann, H.
(2025). How Many Patients with Choroidal Melanoma Would Be Eligible for Neoadjuvant Systemic Therapy to Enable Ruthenium-106 Brachytherapy? Cancers, 17(18), 3022.
https://doi.org/10.3390/cancers17183022